At a glance
RSV monoclonal antibody Coverage, Children 0 to 7 months
RSV monoclonal antibody coverage for children 0 to 7 months is assessed through U.S. jurisdictions' Immunization Information Systems Resources (IIS) data, submitted from jurisdictions to CDC monthly in aggregate by age group.
Monthly estimates shown are cumulative, reflecting all children who received an RSV monoclonal antibody from April 1 through the end of the reporting month.*,† Cumulative estimates include any historical data reported since the previous submission. National estimates are not presented since not all U.S. jurisdictions are currently reporting their IIS data to CDC. Jurisdictions reporting data to CDC include U.S. states, some localities, and territories.
- Figure 5A. Monthly Cumulative Number and Percent of Children <8 Months Who Received 1+ RSV Monoclonal Antibody Doses‡,§ by Jurisdiction, United States. Data Source: U.S. Jurisdiction Immunization Information Systems (IIS).
- Figure 5B. Monthly Cumulative Number and Percent of Children <8 Months Who Received 1+ RSV Monoclonal Antibody Doses‡,§ by Jurisdiction, United States. Data Source: U.S. Jurisdiction Immunization Information Systems (IIS).
Download Data for Figures 5A & 5B
NOTE: Because IIS data are intended to capture all doses administered within a jurisdiction rather than a sample, standard errors are not calculated. Quality and completeness of data may vary across jurisdictions. Laws and policies regarding the submission of vaccination data to an IIS vary by state, which may impact the completeness of vaccination coverage reflected for a jurisdiction.
Coverage estimates based on IIS data are expected to differ from National Immunization Survey-Fall Respiratory Virus Module (NIS-FRVM) estimates for children. NIS-FRVM estimates are based on a sample that may not be representative after survey weighting and vaccination status is determined by survey respondent rather than vaccine records or administrations. In general, NIS-FRVM estimates tend to overestimate coverage due to overreporting and IIS estimates may underestimate coverage due to incompleteness of data in certain jurisdictions. IIS coverage estimates reported on jurisdictions' dashboards may use different criteria for numerators and denominators (e.g. jurisdictions may use IIS-based denominator instead of census population) and thus IIS estimates may differ from those reported on CDC's Weekly RSV Vaccination dashboard.
*RSV monoclonal antibody coverage estimate numerators include the number of children who received at least one dose of either nirservimab or clesrovimab from April 1 through the end of the reporting month. Estimates include children who are deceased but received an RSV monoclonal antibody during the current season. Children receiving doses are attributed to the jurisdiction in which the child resides unless noted otherwise.
†RSV monoclonal antibody coverage denominators for states and localities are obtained from the previous year's U.S. Census Bureau population estimates. For example, population denominators for the 2025–26 season estimate the number of children born since April 1, 2025, using 2024 census data, and are adjusted monthly to allow aging in for infants born each month. Note that in archived versions of dashboards from previous seasons, 2020 U.S. Census estimates were used as denominators for all seasons. Denominators for U.S. territories and freely associated states, including American Samoa, Guam, Marshall Islands, Micronesia, Northern Mariana Islands, Palau, and U.S. Virgin Islands are obtained from: https://www.census.gov/programs-surveys/international-programs/about/idb.html.
‡Some jurisdictions' data are not displayed if they were not available by data retrieval timelines. Data displayed include both valid and invalid doses, persons with last known addresses in the jurisdiction, and persons with unknown addresses within the jurisdiction. Data excludes people whom a provider has indicated have left the jurisdiction. Number of doses administered, and coverage estimates for a given month may change over time for some jurisdictions. New York City (New York) and Philadelphia (Pennsylvania) report data separately from their respective states. New York state data exclude New York City and Pennsylvania state data exclude Philadelphia County. Chicago is a funded jurisdiction; however, their data are reported with Illinois due to lack of a comparable denominator to calculate coverage.
§Figure 5A (line graph) will not display any lines for jurisdictions whose data have not been submitted to CDC; these jurisdictions appear gray in Figure 5B. Some jurisdictions' immunization programs may be aligned to regional virus circulation patterns (e.g., some Pacific Islands may administer nirsevimab or clesrovimab on a different schedule than the continental U.S.).